Methods of treating recurrent ovarian cancer and endometrial cancer with bispecific Anti-muc16 x Anti-cd28 antibodies in combination with Anti-pd-1 antibodies or bispecific Anti-muc16 x Anti-cd3 antibodies
IL328613A0Pending Publication Date: 2026-07-01REGENERON PHARMACEUTICALS INC
0 Cites 0 Cited by
Patent Information
- Application Number
- IL328613
- Authority / Receiving Office
- IL · IL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-20
- Filing Date
- 2024-11-28
- Publication Date
- 2026-07-01
AI Technical Summary
Technical Problem
Current treatments for ovarian cancer and endometrial cancer, particularly recurrent cases, have limited effectiveness due to resistance to platinum-based chemotherapy and insufficient response to PD-1 blockade therapies.
Method used
Administration of a therapeutically effective amount of a bispecific antibody that specifically binds to mucin 16 (MUC16) and CD28 in combination with an anti-PD-1 antibody, or a bispecific antibody that binds to MUC16 and CD3, to enhance immune activation and target cancer cells.
Benefits of technology
The combination therapy effectively inhibits the growth of MUC16-expressing cancers, delays tumor progression, and prevents recurrence, offering a potential solution for cancers resistant to conventional treatments.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of a MUC16-expressing cancer (e.g., ovarian cancer or endometrial cancer). In certain embodiments, the methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody or antigen-binding fragment thereof that specifically binds mucin 16 (MUC16) and CD28 in combination with an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor or a bispecific antibody or antigen-binding fragment thereof that specifically binds MUC16 and CD3.
Need to check novelty before this filing date? Find Prior Art